Adjusted odds ratio 95% CI Diagnostic angiography 0.57 PCI 0.51 CABG

Slides:

Advertisements

Similar presentations

The Influence of Radial vs. Femoral Access on Acute Blood Loss in Patients Undergoing Percutaneous Coronary Intervention Amit Nanda 1, Eric Novak MS 2,

Advertisements

Professor Abdus Samad MD FACC Karachi Institute of Heart Diseases Karachi, Pakistan May 1, 2010.

Patterns of red blood cell transfusion use and outcomes in patients undergoing percutaneous coronary intervention in contemporary clinical practice: Insights.

Date of download: 5/28/2016 Copyright © The American College of Cardiology. All rights reserved. From: Trends in Vascular Complications After Diagnostic.

Date of download: 5/30/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Elective Intra-aortic Balloon Counterpulsation During.

Date of download: 6/27/2016 Copyright © The American College of Cardiology. All rights reserved. From: Percutaneous Coronary Intervention Complications.

Date of download: 7/5/2016 From: Validation of the Appropriate Use Criteria for Coronary Angiography: A Cohort Study Ann Intern Med. 2015;162(8):

From: Contemporary Mortality Risk Prediction for Percutaneous Coronary Intervention: Results From 588,398 Procedures in the National Cardiovascular Data.

Date of download: 9/19/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Association Between Endoscopic vs Open Vein-Graft.

Date of download: 9/19/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Association of Public Reporting for Percutaneous.

Associate Professor, Honorary Consultant Cardiologist

Clinical presentation of myocardial infarction contributes to lower use of coronary angiography in patients with chronic kidney disease D.M. Charytan,

The “occasional open heart surgeon” revisited

The MASS-DAC Study.

Copyright © 2014 American Medical Association. All rights reserved.

The European Society of Cardiology Presented by Dr. Bo Lagerqvist

Successful CTO PCI Associated with Lower Mortality Risk

Copyright © 2009 American Medical Association. All rights reserved.

Scandinavian Simvastatin Survival Study (4S)

The DANAMI-2 Trial Danish Trial in Acute Myocardial Infarction-2

Circ Cardiovasc Interv

Acute Kidney Injury and In-Hospital Mortality after Coronary Artery Bypass Graft versus Percutaneous Coronary Intervention: A Nationwide Study Shen et.

Duration of Dual Antiplatelet Therapy in Patients with an Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Chirag Bavishi, MD, MPH,

Group/causes of death Mortality (%) at 1 year Mortality (%) at 3 years

Clinical presentation of myocardial infarction contributes to lower use of coronary angiography in patients with chronic kidney disease D.M. Charytan,

Figure 1.17 of the 2016 US Renal Data System Annual Data Report, Volume 2, chapter 1 showing the trends in the number of patients with incident ESRD (in.

Early Invasive Versus Initial Conservative Strategies for Women with Non–ST-Elevation Acute Coronary Syndromes: A Nationwide Analysis Islam Y. Elgendy,

Measure Baseline 1 year p Coronary calcium scores

Mean eGFR among survivors after CABG surgery vs all-cause deaths

Probability of cumulative incidence of ESRD, disease-related death, or death from other cause for the entire cohort. Probability of cumulative incidence.

VALUE Trial design: Hypertensive patients at high cardiovascular risk were randomized to valsartan (n = 7,649) vs. amlodipine (n = 7,596). Results (p =

Fewer PCIs After Public Reporting Changes in NY

Relative risk of major events with atenolol vs placebo

Invasive versus conservative treatment in unstable coronary syndromes

Risk of perioperative renal dysfunction with N-acetylcysteine or placebo in patients undergoing CABG surgery End point N-acetylcysteine Placebo Relative.

J. Trevor Posenau, MD, Daniel M. Wojdyla, MS, Linda K

Effect of PCI on 1-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval (bars);

The European Society of Cardiology Presented by RJ De Winter

An Analysis of the ACUITY Trial Lincoff AM, JACC Intv 2008;1:639–48

American College of Cardiology Presented by Dr. Michel R. Le May

4D trial: Primary end point

(p = 0.32 for noninferiority)

Adjusted rate ratios of hospital days and admissions for blacks and Hispanics compared with whites by age group. Adjusted rate ratios of hospital days.

One-year clinical outcomes in older patients with non-ST elevation acute coronary syndrome undergoing coronary angiography: An analysis of the ICON1 study

Global Registry of Acute Coronary Events: GRACE

VALUE: New-onset diabetes in an amlodipine-based vs valsartan-based therapy in high-risk hypertensives Diagnostic criteria Valsartan n (%) Amlodipine n.

ACC/SCAI – i2 Summit Late Breaking Clinical Trials March 29, 2008

National Trends in the Incidence, Management, and Outcomes of Heart Failure Complications in Patients Hospitalized for ST-Segment Elevation Myocardial.

Global patient outcomes after elective surgery: prospective cohort study in 27 low-, middle- and high-income countries British Journal of Anaesthesia

Survival advantage in Asian American end-stage renal disease patients1

Association of hospital coronary artery bypass volume with processes of care, mortality, morbidity, and the Society of Thoracic Surgeons composite quality.

Hisato Takagi, MD, PhD, Hideaki Manabe, MD, Takuya Umemoto, MD, PhD

A decade after the Surgical Treatment for Ischemic Heart Failure (STICH) trial: Weaving firm clinical recommendations from lessons learned Robert E.

Patient characteristics: American vs Canadian transplant patients

P. Michael Grossman et al. JCIN 2009;2:

Body size and outcomes on peritoneal dialysis in the United States

Lynda Anne Szczech, Ira L. Lazar Kidney International

Peter J. Conlon, Mark A. Little, Karen Pieper, Daniel B. Mark

Cox regression of proportion mortality in the first 8 years for patients with three-vessel disease with a significant difference between the treatment.

Davide Capodanno et al. JCIN 2009;2:

Trends in Patient Characteristics and Outcomes of Coronary Artery Bypass Grafting in the 2000 to 2012 Medicare Population Christian McNeely, MD, Stephen.

MRRs and EMRRs for women with ACS

Cost-effectiveness plane for all PARTNER-B vs all ADVANCE and all PARTNER vs ADVANCE high risk comparisons with ICERs from five studies; dashed line represents.

Ticagrelor versus prasugrel; risk ratio with 95% CIs for the primary composite end point, primary composite end point in those undergoing PCI, myocardial.

Effect of PCI on 3 to 5-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval.

Kaplan-Meier estimate of mortality in the two treatment strategies with significant difference between the two groups (log-rank test

Dialysis limitations. Dialysis limitations. (A) Recent data from observational studies and randomized, clinical trials indicate significant limitations.

Effect of intervention differed across racial and socioeconomic groups

Associations of dialysis session length with mortality and hospitalizations. Associations of dialysis session length with mortality and hospitalizations.

Identification of thresholds for significant renal recovery in relation to patient and renal survival. Identification of thresholds for significant renal.

Presentation transcript:

Likelihood of undergoing coronary procedures in dialysis vs nondialysis patients Adjusted odds ratio 95% CI Diagnostic angiography 0.57 0.50-0.60 PCI 0.51 0.43-0.60 CABG 0.44 0.35-0.44 Charytan D. American Society of Nephrology 37th Annual Meeting and Scientific Exposition; October 29-November 1, 2004; St Louis, MO.

In-hospital mortality in dialysis patients after MI with and without interventions In-hospital mortality in dialysis patients undergoing intervention (%) In-hospital mortality in dialysis patients receiving medical therapy only (%) Relative risk (95% CI) Coronary angiography 7.8 16.6 0.56 (0.45-0.69) PCI 6.7 14.3 0.47 (0.32-0.71) CABG 17.9 12.9 1.44 (0.88-2.33) Charytan D. American Society of Nephrology 37th Annual Meeting and Scientific Exposition; October 29-November 1, 2004; St Louis, MO.